STAAR Surgical's China Rebound and Strategic Pivot: From Disruption to Growth
China: The Turn and the Tale of Two High Seasons
STAAR Surgical's second-quarter 2026 results marked a decisive inflection. Net sales of $93.5 million, up 111% year-over-year, were driven by a resurgent China where adoption of EVO Plus exceeded expectations. Warren Foust, now sole CEO, underscored the demand quality: “we saw no evidence of inventory build at distributors or hospitals reinforcing that our growth is being driven by demand.” — Warren Foust, President and Chief Executive Officer · 2026-08-12 This contrasts sharply with prior years of distributor restocking and channel opacity.
The company also offered unusually specific seasonality guidance, noting that Q1 and Q2 are now the strongest quarters in China, while Q3 will dip moderately and Q4 will remain soft. More importantly, management explicitly flagged the non-repeating $25.9 million one-time order from Q3 2025, urging investors to use the adjusted base of $68.8 million for year-over-year comparisons.
This transparency is a welcome shift for a company that previously withdrew guidance and disappointed investors with inventory mishaps.I want to flag for your modeling. Our third quarter of 2025 results included the recognition of $25.9 million related to the 2024 order. On a consolidated basis, third quarter 2025 net sales were $94.7 million. Excluding that item, though, the comparable total base is $68.8 million. That revenue from the 2024 order will not repeat, and we encourage you to use the adjusted base when evaluating third quarter 2026 year-over-year results.
Operational Discipline and the ERP Lift
A second theme is operational maturation. STAAR’s ERP system went live during the quarter, and while it demanded energy, the team delivered record revenue and a return to profitability. The company is also building toward AI-enabled capabilities. ERP system is now a recurring keyword in the call, reflecting management’s focus on scalability. Additionally, restructuring and ERP consulting costs are set to fade, with “We expect the ERP consulting expense to decline significantly beginning in the fourth quarter.” — Deborah Andrews, Executive Vice President and Chief Financial Officer · 2026-08-12 This cost discipline, alongside continued gross margin expansion, underpins the profit story.
From Cautious to Confident: Guidance and the Path Forward
The most notable change is the shift from a guarded tone in prior calls to a constructive, forward-looking one. In May 2026, Foust was still hesitant: “we're just not ready at this point to say, 'Hey, we're certain about everything that's going to happen downstream with all of the stuff that's going on macroeconomically and geopolitically, not just in China, but elsewhere.'” — Warren Foust, Interim Co-CEO, President and Chief Operating Officer · 2026-05-14 Now, he is offering color on Q3 and Q4, and reiterating plans for year-over-year growth in both quarters. This is a stark contrast and signals growing internal confidence. Even the prior discussion on inventory management—where weekly monitoring was introduced—hinted at a structural improvement: “We're looking at inventory on a weekly basis. So we understand much better than we used to.” — Warren Foust, Interim Co-CEO, President and Chief Operating Officer · 2026-03-04 The company now reports
Financially, the company is on solid footing. Cash rose to $181.5 million with no debt, and the revenue trend over the past year shows a sharp rebound from the 2025 trough. With adjusted EBITDA of $20 million and net income of $8.1 million, STAAR is generating meaningful cash flow. Importantly, the company is now investing in the next phase: hiring a chief technology officer, preparing first-in-human studies for next-generation products, and broadening the platform beyond EVO. financial discipline remains a buzzword, but it is now paired with a return to growth.
In essence, STAAR Surgical has transitioned from crisis management to a strategic growth narrative. The China rebound, improved operational execution, and willingness to provide guidance all point to a company that has regained its footing. The key question now is whether the seasonality guidance holds and whether the innovation pipeline can sustain the momentum. For now, the data is encouraging.